Login to Your Account

Study Links ESAs To Higher Leukemia Risk For Some

By Donna Young

Wednesday, December 12, 2007
Erythropoiesis-stimulating agents (ESAs), such as Aranesp, Epogen and Procrit, may increase the risk of acute leukemia in patients with a certain bone marrow disorder, researchers reported at the American Society of Hematology's annual meeting in Atlanta. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription